Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer

Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels

(2019) A. M. Heeren et al.   Journal for ImmunoTherapy of Cancer

Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial

(2018) Sudeep Gupta et al.   JOURNAL OF CLINICAL ONCOLOGY

Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/− neoadjuvant chemotherapy

(2018) He-Yuan Hsieh et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

(2018) Edwin R. Parra et al.   Journal for ImmunoTherapy of Cancer

PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer

(2018) Ying Meng et al.   Journal of Cancer

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

(2018) Yiyi Yan et al.   Frontiers in Immunology

Complex interplay between tumor microenvironment and cancer therapy

(2018) Minhong Shen et al.   Frontiers of Medicine

Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer

(2018) Yun Liang et al.   Diagnostic Pathology

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients

(2017) H. van Meir et al.   OncoImmunology

Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy

(2016) Charlotte S. Lo et al.   CLINICAL CANCER RESEARCH

Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases

(2016) Debbie M. Ferns et al.   Journal for ImmunoTherapy of Cancer

The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome

(2015) Arko Gorter et al.   Journal of Translational Medicine

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response

(2012) C.-L. Chang et al.   CANCER RESEARCH

Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer

(2009) Alessandra Battaglia et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY